Edgar Filing: Fibrocell Science, Inc. - Form 4

Fibrocell Scien Form 4 June 23, 2016	nce, Inc.										
	Л								PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							N OMB Number:	3235-0287			
Check this l if no longer subject to Section 16. Form 4 or Form 5	STATEM	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,							Expires:January 31, 2005Estimated average burden hours per response0.5		
obligations may continu <i>See</i> Instruct 1(b).	ue. Section 17((a) of the l	Public U	Jtility Ho	lding Co		t of 1935 or Section	on			
(Print or Type Res	sponses)										
1. Name and Address of Reporting Person <u>*</u> Mazur Marc			2. Issuer Name and Ticker or Trading Symbol Fibrocell Science, Inc. [FCSC]			-	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)	3. Date of Earliest Transaction (Cl				eck all applicable)				
C/O 405 EAGLEVIEW BLVD.			(Month/Day/Year) 06/22/2016				X_ Director 10% Owner Officer (give title Other (specify below) below)				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
EXTON, PA	19341						Person		1 0		
(City)	(State)	(Zip)	Tal	ble I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
	Transaction Date Ionth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8)	4. Securi onAcquired Disposed (Instr. 3,	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Price	(Insu: 5 and 4)				
Reminder: Report	t on a separate line	e for each cl	ass of sec	curities bene	eficially ow	ned directly	or indirectly.				
					inforı requi	nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ently valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					sposed of, or convertible	Beneficially Owned securities)	1			

1. Title of 2. 3. Transaction Date 3A. Deemed 4. 5. Number of 6. Date Exercisable and 7. Title and Amount of Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative Expiration Date Underlying Securities Security or Exercise any Code Securities (Month/Day/Year) (Instr. 3 and 4) (Instr. 3) Price of (Month/Day/Year) (Instr. 8) Acquired (A)

	Derivative Security				or Dispose (D) (Instr. 3, 4 and 5)					
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 0.95	06/22/2016	A		36,000		<u>(1)</u>	06/22/2026	Common Stock	36,000

Reporting Owners

Reporting Person

Reporting Owner Name / Address	S	Relationships						
	Director	10% Owner	Officer	Other				
Mazur Marc C/O 405 EAGLEVIEW BLVD EXTON, PA 19341). X							
Signatures								
/s/ Marc Mazur 00	5/23/2016							
<u>**</u> Signature of	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) With respect to all 36,000 options, these options vest 100% and become exercisable on the earlier of (x) June 22, 2017 or (y) the date of Fibrocell's 2017 Annual Meeting of Stockholders, subject to the grantee's continued service through the vesting date.
- (2) The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.